Eisai launches U.S. Fycompa oral suspension for patients with swallowing problems

Fycompa tablets

Japan’s Eisai announced the availability in the U.S. of its Fycompa (perampanel) oral suspension for patients who have problems swallowing tablets. The oral suspension, which got FDA approval in April, is a bioequivalent interchangeable alternative to Fycompa tablets.

Fycompa is used as an adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures, and primary generalized tonic-clonic seizures in patients with epilepsy in patients 12 years or older, the company said.

The new oral suspension formulation was developed to provide a new option for patients who have difficulty swallowing tablets. 

Epilepsy affects approximately 2.9 million people in the U.S. Epilepsy is broadly categorized by seizure type, with partial-onset seizures accounting for approximately 60 percent of epilepsy cases and generalized seizures accounting for approximately 40 percent.

In April, Eisai announced it contracted with Russia's PharmStandard to manufacture three of its meds, oncology drugs Halaven and Lenvima and epilepsy med Fycompa. Eisai said the deal calls for PharmStandard to manufacture the cancer meds at its facilities in Ufa, and the seizure product at its plant in Kursk.

- here’s the release

Read more on

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.